<!DOCTYPE html>
<html  >
<head>
  <!-- Site made with Mobirise Website Builder v5.5.2, https://mobirise.com -->
  <meta charset="UTF-8">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="generator" content="Mobirise v5.5.2, mobirise.com">
  <meta name="viewport" content="width=device-width, initial-scale=1, minimum-scale=1">
  <link rel="shortcut icon" href="assets/images/logofnhk-128x130.png" type="image/x-icon">
  <meta name="description" content="Website Builder Description">
  
  
  <title>Tacrine Derivates</title>
  <link rel="stylesheet" href="assets/bootstrap/css/bootstrap.min.css">
  <link rel="stylesheet" href="assets/bootstrap/css/bootstrap-grid.min.css">
  <link rel="stylesheet" href="assets/bootstrap/css/bootstrap-reboot.min.css">
  <link rel="stylesheet" href="assets/tether/tether.min.css">
  <link rel="stylesheet" href="assets/dropdown/css/style.css">
  <link rel="stylesheet" href="assets/socicon/css/styles.css">
  <link rel="stylesheet" href="assets/theme/css/style.css">
  <link rel="preload" href="https://fonts.googleapis.com/css?family=Abel:400&display=swap" as="style" onload="this.onload=null;this.rel='stylesheet'">
  <noscript><link rel="stylesheet" href="https://fonts.googleapis.com/css?family=Abel:400&display=swap"></noscript>
  <link rel="preload" as="style" href="assets/mobirise/css/mbr-additional.css"><link rel="stylesheet" href="assets/mobirise/css/mbr-additional.css" type="text/css">
  
  
  
  
</head>
<body>
  
  <section class="menu cid-sWgKUiWL6B" once="menu" id="menu2-3s">

    

    <nav class="navbar navbar-expand beta-menu navbar-dropdown align-items-center navbar-fixed-top navbar-toggleable-sm bg-color transparent">
        <button class="navbar-toggler navbar-toggler-right" type="button" data-toggle="collapse" data-target="#navbarSupportedContent" aria-controls="navbarSupportedContent" aria-expanded="false" aria-label="Toggle navigation">
            <div class="hamburger">
                <span></span>
                <span></span>
                <span></span>
                <span></span>
            </div>
        </button>
        <div class="menu-logo">
            <div class="navbar-brand">
                <span class="navbar-logo">
                    <a href="home.html">
                        <img src="assets/images/logo-ctbt-color-302x96.png" alt="Mobirise" style="height: 3.8rem;">
                    </a>
                </span>
                
            </div>
        </div>
        <div class="collapse navbar-collapse" id="navbarSupportedContent">
            <ul class="navbar-nav nav-dropdown" data-app-modern-menu="true"><li class="nav-item">
                    <a class="nav-link link text-black text-primary display-4" href="home.html#features17-45">Our Technologies</a>
                </li><li class="nav-item"><a class="nav-link link text-black text-primary display-4" href="home.html#features1-42">About Us</a></li>
                <li class="nav-item">
                    <a class="nav-link link text-black text-primary display-4" href="home.html#testimonials1-41">Our Team</a>
                </li></ul>
            <div class="navbar-buttons mbr-section-btn"><a class="btn btn-sm btn-primary display-4" href="home.html#footer1-44">Contact Us</a></div>
        </div>
    </nav>
</section>

<section class="header1 cid-sVIM8Tv5Yc" id="header16-2g">

    

    <div class="mbr-overlay" style="opacity: 0.7; background-color: rgb(255, 255, 255);">
    </div>

    <div class="container">
        <div class="row justify-content-md-center">
            <div class="col-md-10 align-center">
                <h1 class="mbr-section-title mbr-bold pb-3 mbr-fonts-style display-2">Dually Acting Tacrine Derivatives for Treatment of Neurodegenerative Disorders</h1>
                
                <p class="mbr-text pb-3 mbr-fonts-style display-5">
                    A dually-acting compounds with neuropsychopharmacological and drug-like properties with potential therapeutic use</p>
                <div class="mbr-section-btn"><a class="btn btn-md btn-primary display-4" href="assets/files/Tacrine-Derivates.pdf" target="_blank">DOWNLOAD PDF</a></div>
            </div>
        </div>
    </div>

</section>

<section class="mbr-section content4 cid-sVIM8UR8Y2" id="content4-2h">

    

    <div class="container">
        <div class="media-container-row">
            <div class="title col-12 col-md-8">
                <h2 class="align-center pb-3 mbr-fonts-style display-5">
                    Background</h2>
                <h3 class="mbr-section-subtitle align-center mbr-light mbr-fonts-style display-7">Neurodegenerative disorders (ND) accounts the vast majority of agerelated dementias characterized by progressive cognitive decline of higher mental functions. The research devoted to this field uncovered a pathomechanism of complex multietiology which cannot be addressed by hitting one target.</h3>
                
            </div>
        </div>
    </div>
</section>

<section class="mbr-section content4 cid-sVIM8VNAWr" id="content4-2i">

    

    <div class="container">
        <div class="media-container-row">
            <div class="title col-12 col-md-8">
                <h2 class="align-center pb-3 mbr-fonts-style display-5">
                    Technology Overview</h2>
                <h3 class="mbr-section-subtitle align-center mbr-light mbr-fonts-style display-7">Motivated by currently available treatment against ND involving the inhibitors of acetylcholinesterase (AChE) and N-methyl-D-aspartate receptor (NMDAR), administered also in combination, we developed adually-acting compounds based on 1,2,3,4-tetrahydro-9-aminoacridine (tacrine) structure and confirmed their neuropsychopharmacological and drug-like properties for potential therapeutic use.</h3>
                
            </div>
        </div>
    </div>
</section>

<section class="cid-sVIM8WWmj9" id="image1-2j">

    

    <figure class="mbr-figure container">
        <div class="image-block" style="width: 29%;">
            <img src="assets/images/tacrine-417x293.png" width="1400" alt="Mobirise">
            
        </div>
    </figure>
</section>

<section class="mbr-section content4 cid-sVIM8XOJ8b" id="content4-2k">

    

    <div class="container">
        <div class="media-container-row">
            <div class="title col-12 col-md-8">
                <h2 class="align-center pb-3 mbr-fonts-style display-5">Competing Technologies</h2>
                <h3 class="mbr-section-subtitle align-center mbr-light mbr-fonts-style display-7">Only a few compounds have been established for the treatment of Alzheimer’s disease. For instance, FDA and EMEA have approved three cholinesterase inhibitors, one NMDA-receptor antagonist – memantine and one disease-modifying immunotherapy – aducanumab, for Alzheimer’s disease (AD). Here we offer a combination of both effect in a single molecule. To date there are many other drugs undergoing clinical trials in AD, having various mechanism of action (vaccines against amyloid beta, against Tau protein, antiinflammation drugs) but none of them seems to reach the registration in a short term.</h3>
                
            </div>
        </div>
    </div>
</section>

<section class="mbr-section content4 cid-sVIM8YJta5" id="content4-2l">

    

    <div class="container">
        <div class="media-container-row">
            <div class="title col-12 col-md-8">
                <h2 class="align-center pb-3 mbr-fonts-style display-5">
                    Benefits</h2>
                <h3 class="mbr-section-subtitle align-center mbr-light mbr-fonts-style display-7">Novel molecules represent a new way how to cope with the multiple pathogenic factors of ND. Based on our observations, we suppose that these compounds are able to hit additional targets relevant to ND and thus succeed in overcoming the multifactorial pathogenesis. While tacrine (approved for AD treatment in 1993) was withdrawn from the market due to its hepatotoxicity and other side effects in 2013, our compounds were prepared to avoid this hepatotoxic effect as we demonstrated in in vitro studies. Since these compounds have also been found acting as GluN2B selective NMDAR antagonists, they are therefore believed to hold strong therapeutic potential in the treatment of other disorders – e.g. ischemic damage, chronic pain and depression.</h3>
                
            </div>
        </div>
    </div>
</section>

<section class="mbr-section content4 cid-sVIM92pOG2" id="content4-2n">

    

    <div class="container">
        <div class="media-container-row">
            <div class="title col-12 col-md-8">
                <h2 class="align-center pb-3 mbr-fonts-style display-5">
                    Further Details</h2>
                <h3 class="mbr-section-subtitle align-center mbr-light mbr-fonts-style display-7">Authors would like to thank the grant of Ministry of Education, Youth and Sports of the Czech Republic (project ERDF no. CZ.02.1.01/0.0/0.0/18_069/0010054).<br><br>
<div>
</div><div>1. <a href="https://pubmed.ncbi.nlm.nih.gov/33892271/" class="text-primary">https://pubmed.ncbi.nlm.nih.gov/33892271/</a>
</div><div>2. <a href="https://www.sciencedirect.com/science/article/abs/pii/S0006295221000563?dgcid=rss_sd_all" class="text-primary">https://www.sciencedirect.com/science/article/abs/pii/S0006295221000563?dgcid=rss_sd_all</a>
</div><div>3. <a href="https://www.tandfonline.com/doi/abs/10.1080/01480545.2019.1566350?journalCode=idct20&" class="text-primary">https://www.tandfonline.com/doi/abs/10.1080/01480545.2019.1566350?journalCode=idct20&amp;</a></div></h3>
                
            </div>
        </div>
    </div>
</section>

<section class="mbr-section content4 cid-sVIM93mXUA" id="content4-2o">

    

    <div class="container">
        <div class="media-container-row">
            <div class="title col-12 col-md-8">
                <h2 class="align-center pb-3 mbr-fonts-style display-5">Applications &amp; Opportunity</h2>
                <h3 class="mbr-section-subtitle align-center mbr-light mbr-fonts-style display-7"><p>Neurodegenerative disorders; Alzheimer’s disease.<br><br>Seeking for development or commercial partner or licencing.<br><br><strong>Patent application submitted:</strong><br>&nbsp; &nbsp; &nbsp;Czech patent applications filed ‑ PV 2021‑34</p><p>&nbsp; &nbsp; &nbsp;Czech patent applications filed - PV 2021‑35</p><p>&nbsp; &nbsp; &nbsp;PCT in preparation (priority date 26. 1. 2021)</p></h3>
                
            </div>
        </div>
    </div>
</section>

<section class="cid-sVIM94od3r" id="footer1-2p">

    

    

    <div class="container">
        <div class="media-container-row content text-white">
            <div class="col-12 col-md-3">
                <div class="media-wrap">
                    <a href="home.html">
                        <img src="assets/images/logo-ctbt-color-302x96.png" alt="Mobirise">
                    </a>
                </div>
            </div>
            <div class="col-12 col-md-3 mbr-fonts-style display-7">
                <h5 class="pb-3"></h5>
                <p class="mbr-text"></p>
            </div>
            <div class="col-12 col-md-3 mbr-fonts-style display-7">
                <h5 class="pb-3"><strong>
                    Adress</strong></h5>
                <p class="mbr-text">University Hospital Hradec Králové
<br>Centre for Transfer of Biomedical Technologies
<br>Sokolská 581
<br>500 05 Hradec Králové - Nový Hradec Králové
<br>Czech Republic</p>
            </div>
            <div class="col-12 col-md-3 mbr-fonts-style display-7">
                <h5 class="pb-3"><strong>
                    Contacts</strong></h5>
                <p class="mbr-text">lucie.bartosova@fnhk.cz
<br>+420 727 802 314</p>
            </div>
        </div>
        <div class="footer-lower">
            <div class="media-container-row">
                <div class="col-sm-12">
                    <hr>
                </div>
            </div>
            <div class="media-container-row mbr-white">
                <div class="col-sm-6 copyright">
                    <p class="mbr-text mbr-fonts-style display-7">
                        © All Rights Reserved</p>
                </div>
                <div class="col-md-6">
                    <div class="social-list align-right">
                        <div class="soc-item">
                            <a href="https://twitter.com/rd_uhhk" target="_blank">
                                <span class="mbr-iconfont mbr-iconfont-social socicon-twitter socicon" style="color: rgb(255, 255, 255); fill: rgb(255, 255, 255);"></span>
                            </a>
                        </div>
                        <div class="soc-item">
                            <a href="https://www.facebook.com/fakultninemocnice.hradeckralove" target="_blank">
                                <span class="mbr-iconfont mbr-iconfont-social socicon-facebook socicon" style="color: rgb(255, 255, 255); fill: rgb(255, 255, 255);"></span>
                            </a>
                        </div>
                        <div class="soc-item">
                            <a href="https://www.youtube.com/nemocnicehradec" target="_blank">
                                <span class="mbr-iconfont mbr-iconfont-social socicon-youtube socicon" style="color: rgb(255, 255, 255); fill: rgb(255, 255, 255);"></span>
                            </a>
                        </div>
                        
                        
                        
                    </div>
                </div>
            </div>
        </div>
    </div>
</section><section style="background-color: #fff; font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', 'Roboto', 'Helvetica Neue', Arial, sans-serif; color:#aaa; font-size:12px; padding: 0; align-items: center; display: flex;"><a href="https://mobirise.site/f" style="flex: 1 1; height: 3rem; padding-left: 1rem;"></a><p style="flex: 0 0 auto; margin:0; padding-right:1rem;"><a href="https://mobirise.site/i" style="color:#aaa;">Designed with Mobirise</a> site builder</p></section><script src="assets/popper/popper.min.js"></script>  <script src="assets/web/assets/jquery/jquery.min.js"></script>  <script src="assets/bootstrap/js/bootstrap.min.js"></script>  <script src="assets/tether/tether.min.js"></script>  <script src="assets/smoothscroll/smooth-scroll.js"></script>  <script src="assets/dropdown/js/nav-dropdown.js"></script>  <script src="assets/dropdown/js/navbar-dropdown.js"></script>  <script src="assets/touchswipe/jquery.touch-swipe.min.js"></script>  <script src="assets/theme/js/script.js"></script>  
  
  
</body>
</html>